Skip to main content

Xelstrym FDA Approval History

Last updated by Judith Stewart, BPharm on March 24, 2022.

FDA Approved: Yes (First approved March 22, 2022)
Brand name: Xelstrym
Generic name: dextroamphetamine
Dosage form: Transdermal System
Company: Noven Pharmaceuticals, Inc.
Treatment for: ADHD

Xelstrym (dextroamphetamine) transdermal system is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and children 6 years and older.

Development timeline for Xelstrym

Mar 23, 2022Approval FDA Approves Xelstrym (dextroamphetamine) Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
Feb 22, 2021Noven Submits New Drug Application for Investigational Dextroamphetamine Transdermal System for ADHD

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.